Colombia Pharmaceuticals and Healthcare Report Q2 2009
Business Monitor International, April 2009, Pages: 71
Colombia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Colombia's pharmaceuticals and healthcare industry.
In BMI’s updated Business Environment Ranking table for the Americas, Colombia’s score has remained the same, again ranking the country fifth out of the 10 major markets in the region. While the rising population numbers and a steady forecast market growth represent considerable draws for foreign companies, the persistent problems regarding its intellectual property (IP) environment – as well as the higher attractiveness of other larger and better regulated Latin American markets - will continue to hamper foreign direct investment (FDI) over the coming years.
Colombia’s drug market compound annual growth rate (CAGR) in local currency terms is forecast at a solid 11.56%, similar to the US dollar CAGR, which is expected at 12.04%. In theory, the future ratification of the penned Free Trade Agreement (FTA) by the US should provide a legal basis to continue to improve enforcement to meet its treaty obligations, although continued delays to the ratification of the deal are breeding uncertainty.
On a positive note, there has been an increase in the presence of non-profit organisations addressing Colombia's healthcare needs, to the tune of US$81mn in 2005. In light of mounting evidence of the country's exposure to the global economic downturn, BMI's Country Risk team believes Colombia will be unable to escape a recession in 2009. The GDP growth forecast has been revised downwards, from 2.9% and 4.5% in 2009 and 2010, respectively, to 2.1% and 3.9%. This will further reduce the government's focus on improving the country's healthcare systems, leading to more non-profit institutions entering the country. In fact, given that price rises in private healthcare are the second-largest component of top-line inflation figures, alternative funding sources will be crucial for ensuring adequate access to healthcare and ensuring that certain social groups (such as indigenous and female population) are not further disadvantaged.
Colombian private health insurance firms have recently been criticised for failing to provide care for HIV/AIDS patients. The United Nations Program on AIDS (UNAIDS) has expressed serious concerns over the absence of a transparent national strategy that has left private health insurers with little or no incentives to provide relevant treatments for affected patients. Nevertheless, according to the latest report by UNAIDS on the global HIV/AIDS epidemic, Latin America is performing better in terms of scaling up access to antiretroviral (ARV) drugs compared with rates of coverage in other low- and middle-income countries. However, a perception that the price of treatment in Latin America is high compared with other regions is leading to mounting pressure on Latin America's leaders to talk tough on perceived overpricing of ARVs. A number of non-governmental organisations (NGOs) have already petitioned the Colombian government to issue a compulsory licence for one ARV, following failed requests that its manufacturer voluntarily lowers the drug’s price.
Executive Summary
Colombia Pharmaceutical And Healthcare Industry SWOT
Colombia Political SWOT Analysis
Colombia Economic SWOT Analysis
Colombia Business Environment SWOT Analysis
Pharmaceutical Business Environment Ratings
Table: Americas Pharmaceutical Business Environment Ratings for Q209
Limits To Potential Returns
Risks To Realisation Of Returns
Colombia – Market Summary
Regulatory Regime
Intellectual Property Environment
Counterfeit Pharmaceuticals
Proposed US Free Trade Agreement
Table: Colombia-US FTA Mechanisms Relevant To IP
Pricing And Reimbursement Issues
Other Regulatory Issues
Industry Developments
Epidemiology
Healthcare Sector
Healthcare Insurance
Healthcare Insurance Funding
Pharmaceutical Sector
Recent Pharmaceutical Company Developments
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Table: Colombia - Drug Market Indicators, Historical Data and Forecasts
Key Growth Factors – Industry
Table: Colombia - Health Expenditure Trends, Historical Data and Forecasts
Key Growth Factors – Macroeconomic
Table: Colombia - Economic Activity
Prescription Market Forecasts
Table: Colombia - Prescription Market Indicators, Historical Data and Forecasts (COPmn unless otherwise stated)
Patented Market Forecast
Table: Colombia - Patented Market Indicators, Historical Data and Forecasts
Generics Market Forecast
Table: Colombia - Generic Market Trends, Historical Data and Forecasts
OTC Market Forecasts
Table: Colombia - OTC Market Indicators, Historical Data and Forecasts (COPmn unless otherwise stated)
Pharmaceutical Trade Forecasts
Table: Colombia - Pharmaceuticals Trade Indicators, Historical Data and Forecasts (US$mn)
Medical Device Market Forecast
Table: Colombia – Medical Devices Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)
Other Healthcare Data Forecasts
Table: Colombia – Other Healthcare Data Indicators, Historical Data and Forecasts
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Company Monitor
Leading Multinationals
GlaxoSmithKline (GSK)
Pfizer
Merck & Co
Sanofi-Aventis
Novartis
Indigenous Manufacturers
Tecnoquímicas
Lafrancol
Laboratorios Brussié
Country Snapshot: Colombia Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
- Sanofi-Aventis
- Merck & Co
- GlaxoSmithKline
- Novartis
- Pfizer
- AstraZeneca
- Farmaindustria
- Unimed
- Hersil
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
